Last year, little Regeneron gave its top executives a big payday. The company's vision-loss drug Eylea was breaking sales records left and right. Its colon cancer drug, developed with Sanofi, had hit the market. And the company's board figured that keeping its key people was worth millions–a total of $140 million, in fact, mostly in stock and option awards.
written on 30.04.2014